BR112017019779A2 - composto, e, composição farmacêutica - Google Patents

composto, e, composição farmacêutica

Info

Publication number
BR112017019779A2
BR112017019779A2 BR112017019779A BR112017019779A BR112017019779A2 BR 112017019779 A2 BR112017019779 A2 BR 112017019779A2 BR 112017019779 A BR112017019779 A BR 112017019779A BR 112017019779 A BR112017019779 A BR 112017019779A BR 112017019779 A2 BR112017019779 A2 BR 112017019779A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
salts
compounds
formula
Prior art date
Application number
BR112017019779A
Other languages
English (en)
Other versions
BR112017019779B1 (pt
Inventor
Alexander Brown John
Louise Jones Katherine
G Humphreys Philip
Antonio Bit Rino
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of BR112017019779A2 publication Critical patent/BR112017019779A2/pt
Publication of BR112017019779B1 publication Critical patent/BR112017019779B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

compostos de fórmula (i) e sais dos mesmos: em que r1, r2, r3, r4 são aqui definidos. compostos de fórmula (i) e sais dos mesmos foram descobertos como inibidores da ligação da família bet de proteínas de bromodomínio a, por exemplo, resíduos de lisina acetilados e, portanto, pode ter uso em terapia, por exemplo no tratamento de doenças autoimunes e inflamatórias, tais como artrite reumatoide; e cânceres.
BR112017019779-0A 2015-03-19 2016-03-17 Composto, e, composição farmacêutica BR112017019779B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1504689.9 2015-03-19
GBGB1504689.9A GB201504689D0 (en) 2015-03-19 2015-03-19 Chemical compounds
PCT/EP2016/055792 WO2016146738A1 (en) 2015-03-19 2016-03-17 Benzimidazole derivatives as bromodomain inhibitors

Publications (2)

Publication Number Publication Date
BR112017019779A2 true BR112017019779A2 (pt) 2018-05-22
BR112017019779B1 BR112017019779B1 (pt) 2023-10-03

Family

ID=53052091

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017019779-0A BR112017019779B1 (pt) 2015-03-19 2016-03-17 Composto, e, composição farmacêutica

Country Status (35)

Country Link
US (2) US10442786B2 (pt)
EP (2) EP3271349B1 (pt)
JP (1) JP6419990B2 (pt)
KR (1) KR102072850B1 (pt)
CN (1) CN107635989B (pt)
AR (1) AR103934A1 (pt)
AU (1) AU2016232217B2 (pt)
BR (1) BR112017019779B1 (pt)
CA (1) CA2979504C (pt)
CL (1) CL2017002332A1 (pt)
CO (1) CO2017009992A2 (pt)
CR (1) CR20170430A (pt)
CY (1) CY1121855T1 (pt)
DK (1) DK3271349T3 (pt)
DO (1) DOP2017000213A (pt)
EA (1) EA033594B1 (pt)
ES (1) ES2735417T3 (pt)
GB (1) GB201504689D0 (pt)
HR (1) HRP20191186T1 (pt)
HU (1) HUE044414T2 (pt)
IL (1) IL254318B (pt)
LT (1) LT3271349T (pt)
MA (2) MA41778A (pt)
ME (1) ME03485B (pt)
MX (1) MX2017012023A (pt)
PE (1) PE20180032A1 (pt)
PH (1) PH12017501620A1 (pt)
PL (1) PL3271349T3 (pt)
PT (1) PT3271349T (pt)
RS (1) RS59056B1 (pt)
SG (1) SG11201707356QA (pt)
SI (1) SI3271349T1 (pt)
TW (1) TW201706257A (pt)
UY (1) UY36589A (pt)
WO (1) WO2016146738A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
MX2018001751A (es) 2015-08-11 2018-08-01 Neomed Inst Dihidroquinolinonas aril-sustituidas, su preparacion y su uso como farmaceuticos.
WO2017024406A1 (en) 2015-08-11 2017-02-16 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
MX2018001756A (es) 2015-08-12 2018-09-06 Neomed Inst Benzimidazoles sustituidos, su preparacion y su uso como productos farmaceuticos.
US10501459B2 (en) 2015-10-21 2019-12-10 Neomed Institute Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
WO2017127930A1 (en) 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
GB201614934D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
GB201614940D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
GB201614939D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Ip Dev Ltd Crystalline hydrate
US10617680B2 (en) 2017-04-18 2020-04-14 Celgene Quanticel Research, Inc. Therapeutic compounds
CN109280046B (zh) * 2017-07-21 2021-02-02 浙江海正药业股份有限公司 苯并咪唑类衍生物及其制备方法及其在医药上的用途
JP2021512960A (ja) * 2018-02-06 2021-05-20 シャンハイ ハイファ ファーマシューティカル カンパニー，リミティッド Ｂｅｔ阻害活性を有する化合物並びにその製造方法及び使用
CN109369432B (zh) * 2018-11-02 2021-06-25 永农生物科学有限公司 (s)-4-氯-2-氨基丁酸酯的制备方法
JP2022053557A (ja) * 2019-02-08 2022-04-06 マルホ株式会社 ピリドン誘導体
CN113874017A (zh) * 2019-03-15 2021-12-31 福马治疗股份有限公司 抑制环amp-应答元件结合蛋白(creb)
EP3958867A4 (en) * 2019-04-24 2022-11-02 Convergene Llc SMALL MOLECULAR BROMODOMAIN INHIBITORS AND USES THEREOF
US20220227709A1 (en) * 2019-04-29 2022-07-21 The Board Of Regents Of The University Of Texas System Compositions and methods for treating schistosoma infections

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
DK2007752T3 (da) 2006-03-31 2010-11-15 Janssen Pharmaceutica Nv Benzimidazol-2-yl-pyrimidiner og -pyraziner som modulatorer af histamin H4-receptoren
EP2493310A4 (en) * 2009-10-27 2014-03-12 Glaxosmithkline Llc BENZIMIDAZOLES AS INHIBITORS OF ACID GRAS SYNTHASE
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
DK2624696T3 (en) 2010-10-06 2017-03-13 Glaxosmithkline Llc Corp Service Company BENZIMIDAZOLD DERIVATIVES AS PI3-KINASE INHIBITORS
GB201114103D0 (en) * 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
AU2013365926B9 (en) * 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
PE20151997A1 (es) 2013-03-15 2016-01-13 Plexxikon Inc Compuestos heterociclicos y usos de los mismos
TWI530499B (zh) 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
TWI527811B (zh) * 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
EP3010917B1 (en) * 2013-06-21 2018-01-31 Zenith Epigenetics Ltd. Novel substituted bicyclic compounds as bromodomain inhibitors
US20150051208A1 (en) * 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
US9428515B2 (en) * 2014-05-09 2016-08-30 Boehringer Ingelheim International Gmbh Benzimidazole derivatives
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201504694D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
GB201614939D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Ip Dev Ltd Crystalline hydrate

Also Published As

Publication number Publication date
AR103934A1 (es) 2017-06-14
CN107635989A (zh) 2018-01-26
PH12017501620A1 (en) 2018-02-12
EP3271349A1 (en) 2018-01-24
US10442786B2 (en) 2019-10-15
IL254318A0 (en) 2017-11-30
AU2016232217B2 (en) 2019-04-04
MA46981A (fr) 2019-10-09
SI3271349T1 (sl) 2019-08-30
KR20170129871A (ko) 2017-11-27
CA2979504C (en) 2023-10-10
DK3271349T3 (da) 2019-08-05
MA41778A (fr) 2018-01-24
TW201706257A (zh) 2017-02-16
LT3271349T (lt) 2019-07-10
AU2016232217A1 (en) 2017-10-12
CN107635989B (zh) 2020-12-08
ME03485B (me) 2020-01-20
IL254318B (en) 2019-08-29
BR112017019779B1 (pt) 2023-10-03
US11053212B2 (en) 2021-07-06
PT3271349T (pt) 2019-08-19
HUE044414T2 (hu) 2019-10-28
GB201504689D0 (en) 2015-05-06
CY1121855T1 (el) 2020-07-31
ES2735417T3 (es) 2019-12-18
US20200039953A1 (en) 2020-02-06
EP3549939A1 (en) 2019-10-09
PL3271349T3 (pl) 2019-10-31
DOP2017000213A (es) 2017-10-15
WO2016146738A1 (en) 2016-09-22
CO2017009992A2 (es) 2018-01-05
UY36589A (es) 2016-10-31
HRP20191186T1 (hr) 2019-10-04
PE20180032A1 (es) 2018-01-09
MX2017012023A (es) 2018-01-30
CA2979504A1 (en) 2016-09-22
SG11201707356QA (en) 2017-10-30
CL2017002332A1 (es) 2018-03-16
US20180044317A1 (en) 2018-02-15
KR102072850B1 (ko) 2020-02-03
JP2018507903A (ja) 2018-03-22
RS59056B1 (sr) 2019-08-30
JP6419990B2 (ja) 2018-11-07
EP3271349B1 (en) 2019-05-15
CR20170430A (es) 2017-11-08
EA033594B1 (ru) 2019-11-07
EA201791973A1 (ru) 2018-07-31

Similar Documents

Publication Publication Date Title
BR112017019779A2 (pt) composto, e, composição farmacêutica
CA2999253C (en) Heterocyclic compounds and uses thereof
CL2021000387A1 (es) Compuestos de anillo fusionado
CY1121850T1 (el) Διαρυλο μακροκυκλοι ως ρυθμιστες των πρωτεϊνικων kinασων
CO2021005987A2 (es) Compuestos de anillo fusionado
BR112015031073A2 (pt) inibidores bicíclicos de bromodomínio
EA202091508A1 (ru) 6-азаиндольные соединения
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
EA201792047A1 (ru) Новые соединения
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
BR112016029612A2 (pt) compostos de di-hidroisoquinolinona substituídos
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA202091480A1 (ru) Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
PH12019500460A1 (en) Imidazole derivatives and their use in the treatment of autoimmune or inflammatory diseases or cancers
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
BR112017001334A2 (pt) compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende
EA201790276A1 (ru) Новые имидазопиридазиновые соединения и их применение
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201790349A1 (ru) Производные 6-алкинил-пиридина в качестве миметиков белка smac
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
BR112017018198A2 (pt) inibição da atividade de olig2
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFICACAO DEVIDO A ERRO NO QUADRO 1 RELATIVO AO ITEM 'DESENHOS".

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2016, OBSERVADAS AS CONDICOES LEGAIS